0001213900-22-014569.txt : 20220323 0001213900-22-014569.hdr.sgml : 20220323 20220323180454 ACCESSION NUMBER: 0001213900-22-014569 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220321 FILED AS OF DATE: 20220323 DATE AS OF CHANGE: 20220323 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EMSTER KURT VON CENTRAL INDEX KEY: 0001252524 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39138 FILM NUMBER: 22764115 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD STREET 2: SUITE 350 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jasper Therapeutics, Inc. CENTRAL INDEX KEY: 0001788028 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 842984849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2200 BRIDGE PKWY SUITE #102 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 6505491400 MAIL ADDRESS: STREET 1: 2200 BRIDGE PKWY SUITE #102 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Amplitude Healthcare Acquisition Corp DATE OF NAME CHANGE: 20190912 4 1 ownership.xml X0306 4 2022-03-21 0 0001788028 Jasper Therapeutics, Inc. JSPR 0001252524 EMSTER KURT VON C/O JASPER THERAPEUTICS, INC. 2200 BRIDGE PKWY, SUITE #102 REDWOOD CITY CA 94065 1 0 1 0 Stock Option (right to buy) 3.54 2022-03-21 4 A 0 78045 0.00 A 2032-03-21 Voting Common Stock 78045 78045 D 1/3rd of the shares subject to the option (the "Option") shall vest on December 7, 2022, and 1/3rd of the shares subject to the Option shall vest on each anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. The Reporting Person is a member of the investment committee of Abingworth Bioventures VII, LP ("ABV VII") which approves investment and voting decisions by majority vote. Abingworth LLP provides advisory services to ABV VII and exercises investment and dispositive power over the securities held by ABV VII. Under an agreement between the Reporting Person and Abingworth LLP, the Reporting Person is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of Abingworth LLP. ABV VII may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, Abingworth LLP, ABV VII or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. /s/ Jeet Mahal, as Attorney-in-Fact 2022-03-23